pepdex
← Back to index
№ 039

IGF-1 DES

Truncated IGF-1 variant (missing the first 3 amino acids). Acts more locally than IGF-1 LR3, with shorter duration and (in theory) less systemic exposure.

GH-axis
Evidence: Limited
Half-life
~30 minutes
Route
Subcutaneous, often site-specific
Cycle
4 weeks max
Schedule
Daily, post-workout
In plain English

IGF-1 DES is a shorter version of IGF-1 LR3. It works more locally (near the injection site) and clears faster, which (in theory) means less systemic side-effect exposure than LR3. Used by lifters for site-specific muscle anabolism.

Status & legality
Natty?
Not natty
FDA
Not approved

Not FDA approved. Mecasermin (Increlex) covers IGF-1 generally; DES variant specifically is not approved.

Compounding
Category 2

FDA flagged as significant safety risk; restricted from compounding pharmacies.

WADA
Banned (S2)
Prescribed

Not prescribed in conventional medicine.

Who it's for

  • →Users wanting localized muscle anabolism without LR3-level systemic exposure
  • →Site-specific injection users
  • →Short anabolism windows

What to expect

  1. Week 1

    Pumps and fullness in trained muscle.

  2. Week 4

    Site-specific tightness near worked muscle. Cycle endpoint — stop.

  3. Week 8

    Off-cycle. Reassess.

How it works (mechanism)

Truncated IGF-1 missing the first 3 amino acids. Binds the IGF-1 receptor with normal affinity but has reduced binding to IGFBPs in some tissues. Shorter duration than LR3, often used for site-specific muscle effects.

Dosing protocol

30-150 mcg sub-q post-workout. Often injected near the trained muscle.

Stacks well with

Standalone is preferred over multi-IGF stacking

Side effects

01Hypoglycemia risk (less than LR3 but real)
02Localized growth at injection site
03Headache

When NOT to use

  • ⚠Active malignancy
  • ⚠Diabetic retinopathy
  • ⚠Pregnancy / nursing

Bloodwork to monitor

  • • Fasting glucose every 2 weeks
  • • IGF-1 baseline

Common mistakes

  • • Treating it as IGF-1 LR3 equivalent (different kinetics)
  • • Running longer than 4 weeks
  • • Dosing fasted (hypoglycemia)

Drug & supplement interactions

  • ⚠Insulin: hypoglycemia risk (less than LR3 but real)
  • ⚠Eat near dose; avoid fasting protocols

Educational only. User-specific dosing is between you and a qualified provider.

Frequently asked

What is IGF-1 DES?+
IGF-1 DES is a shorter version of IGF-1 LR3. It works more locally (near the injection site) and clears faster, which (in theory) means less systemic side-effect exposure than LR3. Used by lifters for site-specific muscle anabolism.
Is IGF-1 DES FDA approved?+
Not FDA approved. Mecasermin (Increlex) covers IGF-1 generally; DES variant specifically is not approved.
Is IGF-1 DES banned by WADA?+
IGF-1 DES is on the WADA prohibited list under Banned (S2).
Are you still natty after taking IGF-1 DES?+
No. IGF-1 DES is a performance-enhancing peptide and would disqualify a strict natty claim.
Do doctors prescribe IGF-1 DES?+
Not prescribed in conventional medicine.
What's the typical dose of IGF-1 DES?+
30-150 mcg sub-q post-workout. Often injected near the trained muscle.
What are the side effects of IGF-1 DES?+
Common side effects include: Hypoglycemia risk (less than LR3 but real); Localized growth at injection site; Headache. Less common effects and full safety details are on the entry page.
How long until IGF-1 DES starts working?+
Pumps and fullness in trained muscle.

More in GH-axis

№ 021
HGH (Somatropin)

Recombinant human growth hormone — the protein itself, not a peptide that nudges your body to make more. Highest legal-risk compound in this catalog.

№ 011
MK-677 (Ibutamoren)

Oral ghrelin mimetic. Bumps GH and IGF-1 without injections. Strong appetite stimulation is the trade-off.

№ 006
Ipamorelin

Selective GH secretagogue. Bumps natural GH pulses without hitting cortisol or prolactin.

№ 007
CJC-1295 (no DAC)

GHRH analog. Pairs with Ipamorelin to amplify natural GH pulses. The 'no-DAC' version stays short-acting on purpose.